Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Pieris Pharmaceuticals ( (PIRS) ) has shared an announcement.
Pieris Pharmaceuticals announced the approval of several key proposals during a special stockholder meeting, including a significant increase in authorized shares from 3,750,000 to 200,000,000, and the approval of the 2024 Equity Incentive Plan. Additionally, the company finalized plans for a merger with Palvella Therapeutics, which will result in a name change to Palvella Therapeutics, Inc., potentially enhancing its market positioning and operational capabilities.
More about Pieris Pharmaceuticals
Pieris Pharmaceuticals operates in the biotechnology industry, focusing on the development of therapeutic proteins for various medical conditions.
YTD Price Performance: 14.01%
Average Trading Volume: 20,126
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.92M
Learn more about PIRS stock on TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
